Increased oxidative stress and decreased nitric oxide bioavailability drive endothelial dysfunction in congestive heart failure, representing a critical target for future therapeutic interventions.
Endothelial dysfunction, driven by oxidative stress and reduced nitric oxide bioavailability, is a critical component of systemic vasoconstriction in heart failure and represents an important therapeutic target.
The clinical syndrome of congestive heart failure (CHF) is characterized by abnormalities of left ventricular function and neurohormonal regulation, which are accompanied by effort intolerance, fluid retention, and decreased longevity. While an increased sympathetic tone and an activated renin-angiotensin system may contribute to the reduced vasodilatory capacity in patients with CHF, the important role of the endothelium in coordinating tissue perfusion has now been recognized. CHF is associated with endothelial dysfunction, as demonstrated by impaired endothelium-mediated vasodilation. Endothelial dysfunction in patients with CHF is a critical component in the systemic vasoconstriction and reduced peripheral perfusion that characterizes these patients. Endothelial regulation of vascular tone is mediated mainly by nitric oxide. Increased oxidative stress in patients with CHF is likely caused by decreased bioavailability of nitric oxide due to reduced expression of endothelial nitric oxide synthase and increased generation of reactive oxygen species. These react with nitric oxide in the setting of decreased antioxidant defenses that would normally clear these radicals, culminating in attenuated endothelium-dependent vasodilation in patients with CHF. Therapies that improve endothelial function have been shown to improve exercise tolerance and outcomes in patients with CHF. Endothelial dysfunction is thus an important target for future therapy in patients with CHF.
Sharma et al. (Wed,) conducted a review in Congestive heart failure. Increased oxidative stress and decreased nitric oxide bioavailability drive endothelial dysfunction in congestive heart failure, representing a critical target for future therapeutic interventions.